Published in Clinical Trials Week, July 18th, 2005
"A combined therapy of local recombinant tissue plasminogen activator fibrinolysis and intravenous Abciximab platelet inhibition with additional percutaneous transluminal angioplasty/stenting may improve recanalization and neurological outcome in patients with acute vertebrobasilar occlusion. Combined FAST therapy consisted of intravenous bolus of Abciximab (0.25 mg/kg) followed by a 12-hour infusion therapy (0.125 mcg/kg per...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Clinical Trials Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.